Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Merck (MRK) Shares Rally, Analyst Believes Data Supports Approval of Statercept in PAH
October 10, 2022 11:02 AM EDTMerck (NYSE: MRK) announced positive top-line results from the pivotal Phase 3 STELLAR trial evaluating the safety and efficacy of sotatercept on Monday.
The company said the trial met its primary efficacy outcome measure, demonstrating a statistically significant and clinically meaningful improvement in the six-minute walk distance from baseline at 24 weeks.
Following the news, Mizuho analyst Mara Goldstein maintained a Buy rating and $100 per share price target on the stock, telling investors, "while specific details were not disclosed,... More
